Jonathan Gelfond

4.4k total citations · 1 hit paper
136 papers, 2.8k citations indexed

About

Jonathan Gelfond is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, Jonathan Gelfond has authored 136 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 29 papers in Molecular Biology and 17 papers in Epidemiology. Recurrent topics in Jonathan Gelfond's work include Genetics, Aging, and Longevity in Model Organisms (15 papers), Prostate Cancer Treatment and Research (10 papers) and Renal cell carcinoma treatment (7 papers). Jonathan Gelfond is often cited by papers focused on Genetics, Aging, and Longevity in Model Organisms (15 papers), Prostate Cancer Treatment and Research (10 papers) and Renal cell carcinoma treatment (7 papers). Jonathan Gelfond collaborates with scholars based in United States, Slovakia and China. Jonathan Gelfond's co-authors include Robin J. Leach, Ian M. Thompson, Teresa L. Johnson‐Pais, James F. Nelson, Paula K. Shireman, Ana C. Vallor, Thomas F. Patterson, M. Herrera, David W. Melton and Brian L. Wickes and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jonathan Gelfond

126 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability

2023 140 citations Martin Goros, Jonathan Gelfond et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Gelfond United States	30	933	554	480	373	301	136	2.8k
Jin Lin China	29	766 0.8×	417 0.8×	171 0.4×	147 0.4×	351 1.2×	95	2.8k
Elena Mancini Italy	29	1.6k 1.7×	279 0.5×	301 0.6×	258 0.7×	221 0.7×	108	4.0k
Massimo De Martinis Italy	39	1.0k 1.1×	716 1.3×	244 0.5×	101 0.3×	544 1.8×	111	4.5k
Lia Ginaldi Italy	39	1.1k 1.1×	741 1.3×	274 0.6×	101 0.3×	643 2.1×	121	4.8k
Jiali Han United States	32	1.2k 1.3×	569 1.0×	121 0.3×	150 0.4×	766 2.5×	109	3.7k
Ruby C.Y. Lin Australia	37	2.3k 2.5×	556 1.0×	239 0.5×	63 0.2×	603 2.0×	79	4.8k
Dan L. Longo United States	38	890 1.0×	868 1.6×	528 1.1×	81 0.2×	704 2.3×	76	5.0k
Cristian Pattaro Italy	25	628 0.7×	447 0.8×	241 0.5×	41 0.1×	428 1.4×	84	2.8k
Tal Biron‐Shental Israel	26	375 0.4×	573 1.0×	172 0.4×	66 0.2×	256 0.9×	166	2.4k
Takayuki Yamada Japan	36	728 0.8×	495 0.9×	578 1.2×	60 0.2×	174 0.6×	117	3.6k

Countries citing papers authored by Jonathan Gelfond

Since Specialization

Citations

This map shows the geographic impact of Jonathan Gelfond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Gelfond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Gelfond more than expected).

Fields of papers citing papers by Jonathan Gelfond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Gelfond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Gelfond. The network helps show where Jonathan Gelfond may publish in the future.

Co-authorship network of co-authors of Jonathan Gelfond

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Gelfond. A scholar is included among the top collaborators of Jonathan Gelfond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Gelfond. Jonathan Gelfond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Feng, Jonathan Gelfond, Donald D. McGeary, et al.. (2024). Optimal Tai Chi forms in knee osteoarthritis: An exploration from biomechanical rationale to pain reduction. SHILAP Revista de lepidopterología. 6(3). 100480–100480. 2 indexed citations

Peskoe, Sarah B., Emily Slade, Mary Boulos, et al.. (2024). Methods for building a staff workforce of quantitative scientists in academic health care. Stat. 13(2).

Young, Lyndsay E.A., Jennifer R. Bethard, Dean A. Troyer, et al.. (2024). Determining the N-Glycan and Collagen/Extracellular Matrix Protein Compositions in a Novel Outcome Cohort of Prostate Cancer Tissue Microarrays Using MALDI-MSI. Cancer Research Communications. 4(11). 3036–3048. 4 indexed citations

Cheng, Catherine, et al.. (2023). Prepubertal castration eliminates sex differences in lifespan and growth trajectories in genetically heterogeneous mice. Aging Cell. 22(8). e13891–e13891. 11 indexed citations

Gelfond, Jonathan, et al.. (2023). Causes of death in individuals with trisomy 18 after the first year of life. American Journal of Medical Genetics Part A. 194(2). 279–287. 3 indexed citations

Geller, Robert J., Anna G. Taranova, Roberto Villarreal, et al.. (2022). Disproportionate Burden of COVID-19 Infection Among Hispanic Patients During the First COVID-19 Surge in South Texas. Health Equity. 6(1). 546–553. 3 indexed citations

Wang, Hanzhou, Yan Li, Jonathan Gelfond, et al.. (2022). Stress‐Busting Program for Family Caregivers: Validation of the Spanish version using biomarkers and quality‐of‐life measures. Research in Nursing & Health. 45(2). 205–217. 3 indexed citations

Ramamurthy, Chethan, Martin Goros, Jonathan Gelfond, et al.. (2022). Hereditary Cancer Gene Variants in Hispanic Men With a Personal or Family History of Prostate Cancer. Clinical Genitourinary Cancer. 20(3). 237–243. 4 indexed citations

Wang, Hanzhang, Ronald Rodríguez, Michael A. Liss, et al.. (2022). Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma. International Journal of Clinical Oncology. 27(6). 1068–1076. 15 indexed citations

10.

Ji, Niannian, Neelam Mukherjee, Joshua J. Meeks, et al.. (2021). γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunology Research. 9(12). 1491–1503. 15 indexed citations

11.

McGrath, Jacqueline M., Elizabeth Brownell, Pamela Recto, et al.. (2021). A Meta-Analysis of Breastfeeding Effects for Infants With Neonatal Abstinence Syndrome. Nursing Research. 71(1). 54–65. 10 indexed citations

12.

Chen, Cang, Guo Ge, Jonathan Gelfond, et al.. (2020). Mobilization‐based transplantation of young‐donor hematopoietic stem cells extends lifespan in mice. Aging Cell. 19(3). e13110–e13110. 20 indexed citations

13.

Blanco, Cynthia L., et al.. (2019). Body composition in exclusively human breast milk fed infants: maternal vs. donor expressed breast milk. PEDIATRICS. 144. 614–614. 1 indexed citations

14.

Hernández, Javier, Jonathan Gelfond, Martin Goros, et al.. (2018). The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. PLoS ONE. 13(10). e0204823–e0204823. 7 indexed citations

15.

Dao, Vinh, Yang Liu, Srilakshmi Pandeswara, et al.. (2016). Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells. Cancer Research. 76(20). 5970–5982. 32 indexed citations

16.

Hurez, Vincent, Vinh Dao, Aijie Liu, et al.. (2015). Chronic mTOR inhibition in mice with rapamycin alters T , B , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice. Aging Cell. 14(6). 945–956. 98 indexed citations

17.

Fischer, Kathleen E., Jonathan Gelfond, Vanessa Soto‐Cerrato, et al.. (2015). Health Effects of Long-Term Rapamycin Treatment: The Impact on Mouse Health of Enteric Rapamycin Treatment from Four Months of Age throughout Life. PLoS ONE. 10(5). e0126644–e0126644. 60 indexed citations

18.

Nishijo, Koichi, Qingrong Chen, Lei Zhang, et al.. (2009). Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma. Cancer Research. 69(7). 2902–2911. 66 indexed citations

19.

Beuten, Joke, Jonathan Gelfond, Margarita L. Martínez‐Fierro, et al.. (2009). Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. Carcinogenesis. 30(8). 1372–1379. 35 indexed citations

20.

Beuten, Joke, Jonathan Gelfond, John J. Byrne, et al.. (2008). CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. Carcinogenesis. 29(9). 1751–1757. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact